As the largest international academic Institute dedicated to cancer, the LICR believes that it has a moral obligation to assist in the responsible dissemination and reporting of credible and timely research news and views.
August 6, 2009
Researchers at the San Diego Branch of the Ludwig Institute for Cancer Research and the Moores Cancer Center at the University of California, San Diego have pinpointed a large number of genes that can prevent a type of genetic rearrangement that may lead to cancer and other diseases. The study was published today in the advance online publication of Nature.
July 28, 2009
A comprehensive analysis of nearly 1,600 tumor samples has found that CT-X genes are expressed in nearly half the breast cancers that lack the estrogen receptor. CT-X gene products are the targets of therapeutic cancer vaccines already in phase III clinical trials for lung cancer and melanoma. The study, published this week in the Early Edition of the Proceedings of the National Academy of Sciences, was led by the international Ludwig Institute for Cancer Research (LICR).
May 31, 2009
Jeanne Tie, MD, from the Melbourne Branch of the international Ludwig Institute for Cancer Research was presented with The Bradley Stuart Beller Merit Award at an awards ceremony held at the American Society of Clinical Oncology (ASCO) annual meeting in Florida.
May 28, 2009
Researchers from the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine have uncovered a remarkable property of the contractile ring, a structure required for cell division. Understanding how the contractile ring works to divide the cell may facilitate development of therapies to prevent uncontrolled cell division in cancer.
March 18, 2009
Providing another tool to help to understand gene regulation on a global scale, a nationwide research team has identified and mapped 55,000 enhancers, short regions of DNA that act to enhance or boost the expression of genes. The map, which will be published March 18 in the advance on-line edition of the journal Nature, will help scientists understand how cells control expression of genes specific to their particular cell type.
February 26, 2009
Modern genotyping technologies offer new opportunities to explore how genes influence health and disease, but also present the challenge of analyzing huge amounts of genetic and clinical data. With this in mind, investigators at the Lausanne Branch of the international Ludwig Institute for Cancer Research (LICR), the Swiss Institute of Bioinformatics (SIB) and the University Hospital of Lausanne have developed AssociationViewer, a computational tool that displays genetic differences between individuals on a large scale.
February 3, 2009
While chronic inflammation is widely believed to be a
predisposing factor for colon cancer, the exact mechanisms linking these conditions have remained elusive. Scientists at the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) and the Technical University Munich have jointly discovered a new piece of this puzzle by demonstrating how the Stat3 protein links inflammation to umor
development, a discovery that may well lead to the identification of new therapeutic targets
for colon cancer.
January 28, 2009
Researchers from the J. Craig Venter Institute (JCVI) and the Ludwig Institute for Cancer Research (LICR) have uncovered new genomic alterations that lead to gene fusions in a breast cancer cell line by using 454 Life Sciences sequencing technology.
January 1, 2009
Investigators from the Ludwig Institute for Cancer Research (LICR) Melbourne Center reported today in the journal The Prostate that a potential new reagent could treat prostate tumors with greater specificity and reduced toxicity than many currently used therapies.
November 17, 2008
The international Ludwig Institute for Cancer Research (LICR) announced today that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate to pharmaceutical company Abbott.